Cite
A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.
MLA
Tian, Chenchen, et al. “A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.” International Journal of Molecular Sciences, vol. 23, no. 5, Mar. 2022, p. 2892. EBSCOhost, https://doi.org/10.3390/ijms23052892.
APA
Tian, C., Wei, Y., Li, J., Huang, Z., Wang, Q., Lin, Y., Lv, X., Chen, Y., Fan, Y., Sun, P., Xiang, R., Chang, A., & Yang, S. (2022). A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer. International Journal of Molecular Sciences, 23(5), 2892. https://doi.org/10.3390/ijms23052892
Chicago
Tian, Chenchen, Yufan Wei, Jianjun Li, Zhi Huang, Qiong Wang, Yingxue Lin, Xingping Lv, et al. 2022. “A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.” International Journal of Molecular Sciences 23 (5): 2892. doi:10.3390/ijms23052892.